TenX Keane Acquisition Files Q1 2024 10-Q
Ticker: CTOR · Form: 10-Q · Filed: May 20, 2024 · CIK: 1851484
Sentiment: neutral
Topics: 10-Q, quarterly-report, pharmaceuticals
TL;DR
TenX Keane Acquisition's Q1 2024 10-Q is in. Financials and share details updated.
AI Summary
TenX Keane Acquisition filed its 10-Q for the period ending March 31, 2024. The company, operating in pharmaceutical preparations, reported its financial status. Key financial data and share information, including ordinary shares and rights, were detailed in the filing.
Why It Matters
This filing provides investors with an update on TenX Keane Acquisition's financial health and operational details for the first quarter of 2024.
Risk Assessment
Risk Level: low — The filing is a standard quarterly report and does not indicate any immediate or significant new risks.
Key Numbers
- 0.0001 — Par Value (Par value of ordinary shares and units)
Key Players & Entities
- TenX Keane Acquisition (company) — Filer of the 10-Q
- 0001493152-24-020783 (filing_id) — Accession number for the filing
- 20240331 (date) — Period of report for the 10-Q
- 2834 (industry_code) — Standard Industrial Classification for Pharmaceutical Preparations
- 420 Lexington Ave, Suite 2446, New York, NY 10017 (address) — Business and mailing address of the company
FAQ
What is the primary business of TenX Keane Acquisition?
TenX Keane Acquisition is classified under Pharmaceutical Preparations (SIC code 2834).
What period does this 10-Q filing cover?
This 10-Q filing covers the period ending March 31, 2024.
What are the key components of the company's units?
The company's units consist of one ordinary share and one right, which entitles the holder to receive two-tenths of an ordinary share.
When was the filing submitted?
The filing was submitted on May 20, 2024.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
Filing Stats: 4,667 words · 19 min read · ~16 pages · Grade level 17.9 · Accepted 2024-05-20 17:27:08
Key Financial Figures
- $0.0001 — each consisting of one ordinary share, $0.0001 par value, and one right entitling the
Filing Documents
- form10-q.htm (10-Q) — 516KB
- ex31-1.htm (EX-31.1) — 19KB
- ex31-2.htm (EX-31.2) — 19KB
- ex32-1.htm (EX-32.1) — 9KB
- ex32-2.htm (EX-32.2) — 8KB
- 0001493152-24-020783.txt ( ) — 3345KB
- tenk-20240331.xsd (EX-101.SCH) — 28KB
- tenk-20240331_cal.xml (EX-101.CAL) — 26KB
- tenk-20240331_def.xml (EX-101.DEF) — 159KB
- tenk-20240331_lab.xml (EX-101.LAB) — 221KB
- tenk-20240331_pre.xml (EX-101.PRE) — 191KB
- form10-q_htm.xml (XML) — 400KB
Financial Statements
Financial Statements Consolidated Balance Sheets as of March 31, 2024 (unaudited) and December 31, 2023 F-1 Consolidated F-2 Consolidated 2023 F-3 Consolidated F-4 Notes to Consolidated Financial Statements F-5 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 3 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 6 Item 4.
Controls and Procedures
Controls and Procedures 6
- OTHER INFORMATION
PART II - OTHER INFORMATION Item 1.
Legal Proceedings
Legal Proceedings 7 Item 1A.
Risk Factors
Risk Factors 7 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 7 Item 3. Defaults Upon Senior Securities 7 Item 4. Mine Safety Disclosures 7 Item 5. Other Information 7 Item 6. Exhibits 7
SIGNATURES
SIGNATURES 8 2 PART I – FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS TENX KEANE ACQUISITION CONSOLIDATED BALANCE SHEETS March 31, 2024 (unaudited) December 31, 2023 ASSETS Current Assets: Cash $ 33,330 $ 32,746 Prepaid expenses 61,064 25,454 Total Current Assets 94,394 58,200 Investments held in trust account 48,584,863 72,565,394 Total Assets $ 48,679,257 $ 72,623,594 LIABILITIES AND SHAREHOLDERS' DEFICIT Current Liabilities: Accrued offering costs $ 5,001 $ 5,001 Accrued expenses 488,235 375,886 Note payable - Sponsor 1,520,000 1,320,000 Due to shareholders 268,645 — Due to related party 537,149 344,875 Due to related parties 537,149 344,875 Total Current Liabilities 2,819,030 2,045,762 Commitments and contingencies - - Ordinary shares subject to possible redemption ( 4,312,077 and 6,600,000 shares at $ 11.20 and $ 10.99 per share as of March 31, 2024, and December 31, 2023, respectively) 48,316,218 72,565,394 Shareholders' Deficit: Preferred shares, $ 0.0001 par value; 1,000,000 shares authorized; none issued and outstanding — — Ordinary shares, $ 0.0001 par value; 150,000,000 shares authorized; 2,341,000 shares issued and outstanding (excluding 6,600,000 shares subject to possible redemption) as of March 31, 2024 and December 31, 2023, respectively 167 167 Additional paid-in capital — — Accumulated deficit ( 2,456,158 ) ( 1,987,729 ) Total Shareholders' Deficit ( 2,455,991 ) ( 1,987,562 ) T otal Liabilities and Shareholders' Deficit $ 48,679,257 $ 72,623,594 The accompanying notes are an integral part of these consolidated financial statements. F-1 TENX KEANE ACQUISITION CONSOLIDATED (UNAUDITED) FOR THE THREE MONTHS ENDED MARCH 31, 2024 2023 General and administrative costs $ 268,429 $ 147,922 Operating loss ( 268,429 ) ( 147,922 Other Income Interest income on investments held in trust account